^
    11h
    SKB571-II-02: A Phase II Study of SKB571 in Patients With Lung Cancer (clinicaltrials.gov)
    P2, N=295, Recruiting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | N=190 --> 295
    Enrollment change
    19h
    MRG003-SACC: A Study of Becotatug Vedotin (MRG003) Combined With Epirubicin as Neoadjuvant Therapy for EGFR-Positive, Unresectable Recurrent Sinonasal Adenoid Cystic Carcinoma (clinicaltrials.gov)
    P2, N=40, Recruiting, Eye & ENT Hospital of Fudan University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR expression
    |
    epirubicin • Meiyouheng (becotatug vedotin)
    21h
    ADC and SBRT for Recurrent/Metastatic Salivary Gland Carcinoma (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    Meiyouheng (becotatug vedotin) • Jiataile (sacituzumab tirumotecan)
    23h
    A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy and PD-1/PD-L1 Monoclonal Antibody Therapy(PANKU-BTC01) (clinicaltrials.gov)
    P3, N=538, Not yet recruiting, Sichuan Baili Pharmaceutical Co., Ltd.
    New P3 trial
    |
    5-fluorouracil • capecitabine • oxaliplatin • izalontamab brengitecan (BL-B01D1) • levoleucovorin calcium
    2d
    EGRET: First in Human Study of AZD9592 in Solid Tumors (clinicaltrials.gov)
    P1, N=403, Recruiting, AstraZeneca | Trial completion date: Oct 2027 --> Aug 2028 | Trial primary completion date: Oct 2027 --> Aug 2028
    Trial completion date • Trial primary completion date • First-in-human
    |
    EGFR wild-type
    |
    Avastin (bevacizumab) • Tagrisso (osimertinib) • 5-fluorouracil • leucovorin calcium • tilatamig samrotecan (AZD9592)
    4d
    Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors (clinicaltrials.gov)
    P2, N=480, Recruiting, Shanghai Junshi Bioscience Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Loqtorzi (toripalimab-tpzi) • AWT020
    7d
    JS212 Combination Therapies in Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=80, Recruiting, Shanghai Junshi Bioscience Co., Ltd. | Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2026 --> Dec 2027
    Enrollment open • Trial primary completion date
    |
    Avastin (bevacizumab) • capecitabine • oxaliplatin
    8d
    A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection (clinicaltrials.gov)
    P1/2, N=465, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    13d
    Becotatug Vedotin Plus PD-1 Monoclonal Antibody and Radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma (clinicaltrials.gov)
    P2, N=28, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    Loqtorzi (toripalimab-tpzi) • AiRuiKa (camrelizumab) • Meiyouheng (becotatug vedotin)
    15d
    A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02) (clinicaltrials.gov)
    P2/3, N=90, Not yet recruiting, Sichuan Baili Pharmaceutical Co., Ltd.
    New P2/3 trial
    |
    cisplatin • paclitaxel • 5-fluorouracil • Tevimbra (tislelizumab-jsgr) • izalontamab brengitecan (BL-B01D1)
    17d
    CA2440012: Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer with Disease Progression on or After Immunotherapy (2025-522400-24-00)
    P2/3, N=207, Recruiting, Bristol-Myers Squibb Services Unlimited Company
    New P2/3 trial
    |
    cisplatin • carboplatin • gemcitabine • Neulasta (pegfilgrastim) • izalontamab (SI-B001) • izalontamab brengitecan (BL-B01D1)
    20d
    A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Anti-tumor Efficacy of HDM2024 in Participants With Advanced Solid Tumors (ChiCTR2600121689)
    P1, N=63, Shanghai East Hospital; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
    New P1 trial
    |
    EGFR (Epidermal growth factor receptor) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)